Nightingale Health's Annual Report for financial year 2025-2026 has been published
Nightingale Health Plc | Stock Exchange Release | October 01, 2026 at 08:30:00 EEST
Nightingale Health Plc’s Annual Report for financial year 1 July 2025–30 June 2026 has been published. The publication includes the Board of Directors' Report, the Consolidated and Parent Company Financial Statements, the Corporate Governance Statement, and the Remuneration Report.
The Annual Report is attached to this release, and is also available on Nightingale Health’s website https://ir.nightingalehealth.com/financial-reports. The Corporate Governance Statement will be available also at https://ir.nightingalehealth.com/corporate-governance-statements, and the Remuneration Report at https://ir.nightingalehealth.com/remuneration-reports.
Nightingale Health Plc publishes the financial statements also in XHTML format in accordance with the European Single Electronic Format (ESEF) reporting requirements. In line with the ESEF requirements, the primary statements in the consolidated financial statements have been labelled with XBRL tags. Notes to financial statements have been labelled with XBRL block tags. The audit firm PricewaterhouseCoopers Oy has provided an independent auditor’s reasonable assurance report on Nightingale Health’s ESEF Financial Statements in accordance with ISAE 3000 (Revised). The ESEF financial statements in Finnish are available in the zip file attached to this release and at https://ir.nightingalehealth.com/financial-reports.
For further information, please contact
Teemu Suna, CEO
ir@nightingalehealth.com
About Nightingale Health
Chronic diseases cause around 75% of deaths globally and place a growing burden on healthcare systems. The way to address this is preventive healthcare, but until recently the tools to detect disease risks at population scale have not existed. Nightingale Health has built them. The Nightingale Health Check is a blood-based risk detection test that identifies risks for multiple chronic diseases, including cardiovascular disease, type 2 diabetes, kidney disease, and fatty liver disease, from a single blood sample. It is designed to be applied population-wide, so healthcare systems can identify the people who would benefit most from preventive action before disease develops.
Nightingale Health's technology is validated in over 1,000 peer-reviewed scientific publications and is used in many of the world's leading health studies, including the UK Biobank. In Finland, the Nightingale Health Check is in nationwide healthcare use, and over 250,000 people have already received their results. Nightingale Health operates globally with a parent company in Finland and subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom, and has customers in more than 34 countries across healthcare and medical research. The company's Series B shares are listed on the Main Market of Nasdaq Helsinki and on the OTCQX International market. Read more: https://nightingalehealth.com/
Image Attachments
Nightingale Health
